Lv55
826 积分 2023-12-13 加入
Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma
13天前
已完结
For Whom the Bell Tolls? A Toll-Like Receptor 9 Agonist's Journey from Vaccine Adjuvant to Promising Agent in Anti–PD-1–Resistant Melanoma
14天前
已完结
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor–induced thrombocytopenia
14天前
已完结
Mechanisms of HDAC inhibitor-induced thrombocytopenia
14天前
已完结
Biomarker-driven management strategies for peripheral T cell lymphoma
14天前
已完结
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
14天前
已完结
Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
14天前
已完结
PO002/#156 Efficacy and safety results from skyscraper-04: an open-label randomized phase 2 trial of tiragolumab plus atezolizumab for PD-L1-positive recurrent cervical cancer
24天前
已关闭
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial
24天前
已完结
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
24天前
已完结
皖公网安备34019202002308
